Therapeutic use of the high-density lipoprotein protein and peptides.
High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the novel techniques of coronary evaluation. A number of reports have examined the potential therapeutic properties of the synthetic HDLs prepared by complexing recombinant apolipoprotein (apo) A-I(Milano), a variant form of native apoA-I, with phospholipids. The availability of synthetic HDL complexes containing recombinant apoA-I(Milano) has opened up a new era of therapeutic management for coronary disease. HDL formulations of recombinant apoA-I(Milano)-phospholipid complexes have clearly shown rapid regression of a focal carotid atheroma as well as powerful protection from myocardial infarction in a rabbit model. In a pilot study, ETC-216 showed a significant reduction in coronary plaque burden after five weekly treatments, assessed by intravascular ultrasound in patients with acute coronary syndrome. Other therapeutic options of HDL therapy have recently became available.
Marchesi
Marta
M
Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy. Marta.Marchesi@unimi.it
Sirtori
Cesare R
CR
D000818:Animals; D016632:Apolipoprotein A-I / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy / Q000473:pathology; D003327:Coronary Disease / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008075:Lipoproteins, HDL / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D010713:Phosphatidylcholines / Q000627:therapeutic use
D016632:Apolipoprotein A-I; C474616:ETC216; D008075:Lipoproteins, HDL; D010455:Peptides; D010713:Phosphatidylcholines